Trial Profile
A Phase 1, Exploratory, Randomized, Double-Blind, Two-Way Cross Over Study to Assess Pharmacokinetic and Pharmacodynamic Effects of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Subjects With Type 1 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Gan&Lee Pharmaceuticals
- 25 Jan 2017 Status changed from recruiting to completed.
- 08 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016.
- 08 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Aug 2016.